Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis

Keyphrases

• Ulcerative Colitis 100%
• Janus Kinase Inhibitors 100%
• Tofacitinib 100%
• Janus Kinase 33%
• Inflammatory Pathways 16%
• Pharmacokinetic Properties 16%
• Signaling Cascades 16%
• Kinase Cascade 16%
• Therapeutic Potential 16%
• Remission 16%
• Complex Etiology 16%
• Janus Kinase 1 (JAK1) 16%
• Chronic Treatment 16%
• Cytokine Signaling 16%
• Inflammatory Bowel Disease 16%
• Safety Data 16%
• Disease Cycle 16%
• Property Data 16%
• Environmental Genetics 16%
• Kinase Family 16%
• Place in Therapy 16%
• Efficacy Data 16%
• JAK3 16%
• Safety Potential 16%
• Gastrointestinal Inflammation 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Ulcerative Colitis 100%
• Tofacitinib 100%
• Janus Kinase Inhibitor 100%
• Janus Kinase 33%
• Cytokine 16%
• Disease 16%
• Symptom 16%
• Pharmacokinetics 16%
• Remission 16%
• Inflammatory Bowel Disease 16%
• Digestive System Inflammation 16%
• Cefaclor 16%

Biochemistry, Genetics and Molecular Biology

• Janus Kinase Inhibitor 100%
• Tofacitinib 100%
• Janus Kinase 66%
• Signal Transduction 33%
• Genetics 33%
• Cytokine 33%
• Pharmacokinetic Properties 33%